Combination Anti–PD-L1 and Anti–CTLA-4 Immunotherapy in Advanced Liver Cancer
Posted: 02/24/2022 | By: Chase Doyle

Question 1 of 5

The STRIDE regimen—a single priming dose of T (anti–CTLA-4) added to D (anti–PD-L1); Single T Regular Interval D, formerly T300+D—is an alternative to which standard of care in patients with advanced hepatocellular carcinoma?

Choose 1